Apollo Cancer Centre Launches India’s First LungLife Screening Programme To Tackle Lung Cancer

Apollo Cancer Centres (ACCs) has introduced India's first LungLife Screening Programme, a transformative initiative aimed at the early detection of lung cancer. With lung cancer accounting for 5.9 per cent of all cancers and 8.1 per cent of cancer-related deaths in India, this programme seeks to improve survival rates by diagnosing the disease at a treatable stage.

According to GLOBOCAN 2020, lung cancer remains the leading cause of cancer deaths globally, responsible for 1.8 million fatalities or 18 per cent of total cancer-related deaths. Despite this alarming statistic, 80 per cent of high-risk individuals have never discussed lung cancer screening with their healthcare providers, highlighting the urgent need to raise awareness and improve access to early detection measures.

The LungLife Screening Programme is tailored for individuals aged between 50 and 80 years who are asymptomatic but have significant risk factors. These include a history of smoking, exposure to passive smoking, or a family history of lung cancer. Utilising low-dose computed tomography (LDCT), the programme prioritises early detection while minimising radiation exposure, thus ensuring patient safety.

Experts Stress the Importance of Early Detection

Dr Nikhil Modi, Senior Consultant in Pulmonology at Apollo Cancer Centre, New Delhi, emphasised the life-saving potential of early detection. “Lung cancer is among the deadliest cancers globally, but catching it early dramatically improves survival chances. With the LungLife Screening Programme, we are focusing on high-risk individuals, using advanced LDCT technology to detect lung cancer at a treatable stage. This initiative empowers patients with better treatment outcomes and fosters hope for a healthier future.”

Dr Manish Singhal, Senior Consultant in Medical Oncology, echoed these sentiments, describing the initiative as a pivotal step in addressing the rising lung cancer burden. “This comprehensive programme leverages state-of-the-art technology to deliver accurate diagnoses while prioritising patient safety. By focusing on early-stage detection, we exponentially increase the chances of effective treatment and recovery. Our goal is not just to treat cancer but to transform lives through timely interventions and holistic care.”

Adding to the discussion, Dr SVS Deo, Lead and Senior Consultant in Surgical Oncology, highlighted the often silent progression of lung cancer. “Lung cancer frequently remains undiagnosed until it reaches advanced stages, making early detection a critical intervention. This programme combines precision diagnostics with patient-centred care, improving survival rates and redefining excellence in cancer treatment.”

A Commitment to Redefining Oncology Care

Shivakumar Pattabhiraman, Managing Director of Indraprastha Apollo Hospitals, underscored Apollo Cancer Centre’s leadership in oncology. “We are proud to pioneer the LungLife Screening Programme in India. This initiative is not only about saving lives but also about empowering individuals with the knowledge and tools to prioritise their health.”

With a legacy spanning over three decades, Apollo Cancer Centres has consistently set benchmarks in cancer care. The network comprises over 390 oncologists delivering organ-based treatment approaches across India. Apollo is also home to South Asia’s first Pencil Beam Proton Therapy Centre, attracting patients from 147 countries.

The LungLife Screening Programme reflects Apollo Cancer Centre’s steadfast mission to elevate cancer care standards and inspire collective action against lung cancer nationwide.